Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Transplantation ; 106(9): 1728-1729, 2022 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-35417114
4.
Am J Surg Pathol ; 35(6): 807-15, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21552113

RESUMO

The 2008 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues defines monomorphic posttransplant lymphoproliferative disorders (M-PTLDs) as lymphoid or plasmacytic proliferations that fulfill the criteria for one of the B-cell or T/NK-cell neoplasms recognized in immunocompetent patients. However, indolent B-cell lymphomas, such as extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), are specifically excluded from this category. In this study, we describe the clinicopathologic features of 4 posttransplant lymphoma-like proliferations that were Epstein-Barr virus (EBV) positive, but were otherwise completely typical for a MALT lymphoma. The 4 patients (age, 12 to 71 y) had received solid organ transplants (2 hearts, 1 kidney, 1 kidney/pancreas) at a median of 116 months before presentation, and had been maintained on varying immunosuppressive regimens that included cyclosporine, azathioprine, tacrolimus, and sirolimus. Three of the 4 patients presented with solitary subcutaneous masses, whereas the fourth patient presented with a solitary orbital soft tissue mass. All the 4 cases were morphologically typical for MALT lymphoma, demonstrated plasmacytic differentiation with IgA heavy chain restriction (3 cases κ positive, 1 case λ positive), and were diffusely EBV-encoded small RNA positive. Patients were followed for a median of 44.9 months, and all achieved a complete response following various regimens that included reduced immunosuppression with or without antiviral therapy, local surgical excision, rituximab, or local radiation therapy. The uniform EBV positivity and response to immune reconstitution in some cases suggest that EBV-positive MALT lymphomas arising in the posttransplant setting should be included among PTLDs. Whether their distinctive subcutaneous/soft tissue localization and IgA positivity are uniform features will require identification of additional cases.


Assuntos
Infecções por Vírus Epstein-Barr/patologia , Herpesvirus Humano 4/isolamento & purificação , Linfoma de Zona Marginal Tipo Células B/patologia , Transplante de Órgãos/efeitos adversos , Neoplasias de Tecidos Moles/patologia , Adulto , Idoso , Antivirais/uso terapêutico , Criança , Terapia Combinada , Infecções por Vírus Epstein-Barr/complicações , Infecções por Vírus Epstein-Barr/virologia , Feminino , Genótipo , Transplante de Coração/efeitos adversos , Herpesvirus Humano 4/genética , Humanos , Imunossupressores/uso terapêutico , Hibridização in Situ Fluorescente , Transplante de Rim/efeitos adversos , Doenças Linfáticas/patologia , Doenças Linfáticas/virologia , Linfoma de Zona Marginal Tipo Células B/etiologia , Linfoma de Zona Marginal Tipo Células B/terapia , Linfoma de Zona Marginal Tipo Células B/virologia , Masculino , Transplante de Pâncreas/efeitos adversos , Complicações Pós-Operatórias , RNA Viral/genética , RNA Viral/isolamento & purificação , Radioterapia , Neoplasias de Tecidos Moles/etiologia , Neoplasias de Tecidos Moles/terapia , Neoplasias de Tecidos Moles/virologia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA